THE NON-INVASIVE VAGUS NERVE STIMULATION DEVICE PROVIDES A NEW TREATMENT OPTION FOR MILLIONS WITH MIGRAINE
The vagus nerve stimulation device was first approved by the FDA in April 2017 for the acute treatment of episodic cluster headaches. January 2018, announcement of the new Migraine treatment marks gammaCore’s first approval for Migraine.
- gammaCore® (nVNS) is a non-invasive, hand-held medical device that treats the acute pain of a cluster headache attack or a Migraine attack by stimulating the vagus nerve.
- The device is held to the neck and mild electrical currents pass through the skin to stimulate the fibers of the vagus nerve, a large nerve system that connects the gut to the brain . gammaCore passed the test in clinical studies as a new Migraine treatment, showing a significant reduction in acute Migraine or cluster headache pain after use of the device.
· gammaCore is the third neuromodulation device approved by the FDA for acute Migraine treatment. Cefaly ACUTE was approved for acute use in September 2017. Meanwhile, eNeura’s TMS unit was approved for acute use in December 2013. While each device operates differently, they all offer patients the option of aborting a migraine attack without drugs, and minimal side effects.
Call The Manhattan Center For Headache & Neurology to find out more about this device! We look forward to seeing you!
By: Rajni Bala, NP